References
- Mueck AO, Seeger H, Wallweiner D. Impact of hormone replacement therapy on endogenous estrodial metabolism in postmenopausal women. Maturitus 2002;43:87–93.
- Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD. Mammogrphic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002;9:110–116.
- Morabia A, Costanza MC. Recent reversal of trends in hormone therapy use in a European population. Menopause 2006;13:111–115.
- Rossouw JE, Anderson GL, Prentice RL, La Croix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
- Bhavnani BR, Strickler RC. Menopausal hormone therapy. J Obstet Gynaecol Can 2005;27:137–162.
- Dai S, Duan J, Lu Y, Zhang Y, Cheng J, Ren J, Zhao X, Wu Y, Yu Y, Zuo P, et al Phytoestrogen α-Zearalanol inhibits the progression of atherosclerosis and improves lipid profile in ovariectomized cholesterol-fed rabbits. Endocrine 2004;25:121–129.
- Altavilla D, Saitta A, Galeano M, Squadrito G, Marino D, Minutoli L, Calapai G, Deodato B, D'Anna R, Corrado F, Caputi AP, et al The phytoestrogen alpha-zearalenol reverses endothelial dysfunction induced by oophorectomy in rats. Lab Inves 2001;81:125–132.
- Dai S, Duan J, Lu Y, Zhang Y, Cheng J, Ren J, Deng W, Wu Y. α-Zearalanol, a phytoestrogen for cardiovascular therapy. Endocrine 2004;25:117–119.
- Deng WH, Wu YY, Duan JH, Yang L, Wang S, Dai SL. Effects of phytoestrogen alpha-zearalanol on normal human breast. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004;26:566–570.
- Deng Wenhui, Wu Yiyong, Zhang Yi, Li Yanchun, Ma Zhengzhong. The study of effects of estradiol benzoate on breast using nude mice xenograft models of normal human breast tissues. Natl Med J China 2003;83:81–82.
- Deng Wenhui, Lu Xu, Wu Yiyong, Li Yanchun, Yang Li. The effect of estrogen benzoate on normal human breast tissue implanted into athymic nude mice. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2003;25:70–73.
- Blancato J, Singh B, Liu A, Liao DJ, Dickson RB. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer 2004;90:1612–1619.
- Yuri T, Tsukamoto R, Miki K, Uehara N, Matsuoka Y, Tsubura A. Biphasic effects of zeranol on the growth of estrogen receptor-positive human breast carcinoma cells. Oncol Rep 2006;16:1307–1312.
- Wagner J, Lehmann L. Estrogens modulate the gene expression of Wnt-7a in cultured endometrial adenocarcinoma cells. Mol Nutr Food Res 2006;50:368–372.
- Withanage GS, Murata H, Koyama T, Ishiwata I. Agonistic and antagonistic effects of zearalenone, an etrogenic mycotoxin, on SKN, HHUA, and HepG2 human cancer cell lines. Vet Hum Toxicol 2001;43:6–10.
- Wang LH, Yang XY, Zhang X, Mihalic K, Xiao W, Farrar WL. The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity. Cancer Res 2003;63:2046–2051.
- Kurebayashi J, Okubo S, Yamamoto Y, Sonoo H. Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer 2004;11:38–41.
- Hulka BS, Liu ET, Lininger RA. Steroid hormones and risk of breast cancer. Cancer (supplement) 1994;74:1111–1124.
- Mustafa IA, Bland KI. Physiologic effects of steroid hormones and postmenopausal hormone replacement on the female breast and breast cancer risk. Ann Surg 1998;228:638–651.
- Meng FJ, Han YZ, Que YM, Wang H. Progress in plant growth regulation. In: Karssen CM, VanLoon C, Vreugdennilced SD, editors. Netherland: Kluwer Acedemic Publisher; 1992. pp 291–297.